115 related articles for article (PubMed ID: 28492659)
1. Ensemble clustering of phosphoproteomic data identifies differences in protein interactions and cell-cell junction integrity of HER2-overexpressing cells.
Schaberg KE; Shirure VS; Worley EA; George SC; Naegle KM
Integr Biol (Camb); 2017 Jun; 9(6):539-547. PubMed ID: 28492659
[TBL] [Abstract][Full Text] [Related]
2. Phosphoproteomic analysis of Her2/neu signaling and inhibition.
Bose R; Molina H; Patterson AS; Bitok JK; Periaswamy B; Bader JS; Pandey A; Cole PA
Proc Natl Acad Sci U S A; 2006 Jun; 103(26):9773-8. PubMed ID: 16785428
[TBL] [Abstract][Full Text] [Related]
3. Prolactin modulates phosphorylation, signaling and trafficking of epidermal growth factor receptor in human T47D breast cancer cells.
Huang Y; Li X; Jiang J; Frank SJ
Oncogene; 2006 Dec; 25(58):7565-76. PubMed ID: 16785991
[TBL] [Abstract][Full Text] [Related]
4. EGFR signaling to p120-catenin through phosphorylation at Y228.
Mariner DJ; Davis MA; Reynolds AB
J Cell Sci; 2004 Mar; 117(Pt 8):1339-50. PubMed ID: 14996911
[TBL] [Abstract][Full Text] [Related]
5. Phosphoproteomic analysis of Syk kinase signaling in human cancer cells reveals its role in cell-cell adhesion.
Larive RM; Urbach S; Poncet J; Jouin P; Mascré G; Sahuquet A; Mangeat PH; Coopman PJ; Bettache N
Oncogene; 2009 Jun; 28(24):2337-47. PubMed ID: 19421152
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of ErbB2 receptor inhibits IGF-I-induced Shc-MAPK signaling pathway in breast cancer cells.
Lu Y; Zi X; Zhao Y; Pollak M
Biochem Biophys Res Commun; 2004 Jan; 313(3):709-15. PubMed ID: 14697248
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of HER2-induced endothelial cell retraction.
Carter WB; Niu G; Ward MD; Small G; Hahn JE; Muffly BJ
Ann Surg Oncol; 2007 Oct; 14(10):2971-8. PubMed ID: 17593333
[TBL] [Abstract][Full Text] [Related]
8. Geldanamycin destabilizes HER2 tyrosine kinase and suppresses Wnt/beta-catenin signaling in HER2 overexpressing human breast cancer cells.
Wang K; Ma Q; Ren Y; He J; Zhang Y; Zhang Y; Chen W
Oncol Rep; 2007 Jan; 17(1):89-96. PubMed ID: 17143483
[TBL] [Abstract][Full Text] [Related]
9. Protein kinase C α enhances migration of breast cancer cells through FOXC2-mediated repression of p120-catenin.
Pham TND; Perez White BE; Zhao H; Mortazavi F; Tonetti DA
BMC Cancer; 2017 Dec; 17(1):832. PubMed ID: 29216867
[TBL] [Abstract][Full Text] [Related]
10. PTPN13 induces cell junction stabilization and inhibits mammary tumor invasiveness.
Hamyeh M; Bernex F; Larive RM; Naldi A; Urbach S; Simony-Lafontaine J; Puech C; Bakhache W; Solassol J; Coopman PJ; Hendriks WJAJ; Freiss G
Theranostics; 2020; 10(3):1016-1032. PubMed ID: 31938048
[TBL] [Abstract][Full Text] [Related]
11. HER2 mediates epidermal growth factor-induced down-regulation of E-cadherin in human ovarian cancer cells.
Cheng JC; Qiu X; Chang HM; Leung PC
Biochem Biophys Res Commun; 2013 Apr; 434(1):81-6. PubMed ID: 23542467
[TBL] [Abstract][Full Text] [Related]
12. Expression of Wnt3 activates Wnt/β-catenin pathway and promotes EMT-like phenotype in trastuzumab-resistant HER2-overexpressing breast cancer cells.
Wu Y; Ginther C; Kim J; Mosher N; Chung S; Slamon D; Vadgama JV
Mol Cancer Res; 2012 Dec; 10(12):1597-606. PubMed ID: 23071104
[TBL] [Abstract][Full Text] [Related]
13. The interplay of HER2/HER3/PI3K and EGFR/HER2/PLC-γ1 signalling in breast cancer cell migration and dissemination.
Balz LM; Bartkowiak K; Andreas A; Pantel K; Niggemann B; Zänker KS; Brandt BH; Dittmar T
J Pathol; 2012 Jun; 227(2):234-44. PubMed ID: 22262199
[TBL] [Abstract][Full Text] [Related]
14. E-cadherin surface levels in epithelial growth factor-stimulated cells depend on adherens junction protein shrew-1.
Gross JC; Schreiner A; Engels K; Starzinski-Powitz A
Mol Biol Cell; 2009 Aug; 20(15):3598-607. PubMed ID: 19515834
[TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
[TBL] [Abstract][Full Text] [Related]
16. Transforming growth factor {beta} (TGF-{beta})-Smad target gene protein tyrosine phosphatase receptor type kappa is required for TGF-{beta} function.
Wang SE; Wu FY; Shin I; Qu S; Arteaga CL
Mol Cell Biol; 2005 Jun; 25(11):4703-15. PubMed ID: 15899872
[TBL] [Abstract][Full Text] [Related]
17. Compartmentalization in membrane rafts defines a pool of N-cadherin associated with catenins and not engaged in cell-cell junctions in melanoma cells.
Rossier-Pansier L; Baruthio F; Rüegg C; Mariotti A
J Cell Biochem; 2008 Feb; 103(3):957-71. PubMed ID: 17668445
[TBL] [Abstract][Full Text] [Related]
18. Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance.
Zhou H; Kim YS; Peletier A; McCall W; Earp HS; Sartor CI
Int J Radiat Oncol Biol Phys; 2004 Feb; 58(2):344-52. PubMed ID: 14751502
[TBL] [Abstract][Full Text] [Related]
19. ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells.
Anido J; Matar P; Albanell J; Guzmán M; Rojo F; Arribas J; Averbuch S; Baselga J
Clin Cancer Res; 2003 Apr; 9(4):1274-83. PubMed ID: 12684395
[TBL] [Abstract][Full Text] [Related]
20. TOB1 is regulated by EGF-dependent HER2 and EGFR signaling, is highly phosphorylated, and indicates poor prognosis in node-negative breast cancer.
Helms MW; Kemming D; Contag CH; Pospisil H; Bartkowiak K; Wang A; Chang SY; Buerger H; Brandt BH
Cancer Res; 2009 Jun; 69(12):5049-56. PubMed ID: 19491269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
